Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00416949 · ClinicalTrials.gov registry record · NA
Iodine I 131 in Treating Patients With Thyroid Cancer
A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT00416949 is a NA study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 9 participants.
The verdict
NCT00416949, a NA study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation. PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 works in treating patients with thyroid cancer.
Interventions
- DEVICE Patient-specific dosimetry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00416949
The ClinicalTrials.gov registry entry for NCT00416949 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patient-specific dosimetry is the first listed.
NCT00416949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00416949 about?
NCT00416949 is a clinical study titled "Iodine I 131 in Treating Patients With Thyroid Cancer". RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation. PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 works in treating patients with thyroid cancer.
What is the current status of trial NCT00416949?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2006-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00416949?
The interventions under investigation include: Patient-specific dosimetry (DEVICE).
Who is sponsoring clinical trial NCT00416949?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.